Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia

Journal of Anxiety Disorders

Volumn 22, Issue 1, 2008, Pages 88-97

  Mrakotsky, Christine ^a   Masek, Bruce ^b   Biederman, Joseph ^b   Raches, Darcy ^a   Hsin, Olivia ^a   Forbes, Peter ^a   de Moor, Carl ^a   DeMaso, David Ray ^a   Gonzalez Heydrich, Joseph ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Children; Mirtazapine; Pharmacological treatment; Social anxiety disorder

Indexed keywords

HERBACEOUS AGENT; MIRTAZAPINE;

ADOLESCENT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BEDTIME DOSAGE; CHILD PSYCHIATRY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; IRRITABILITY; LEARNING DISORDER; MALE; OPEN STUDY; PILOT STUDY; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; SCHOOL CHILD; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYMPTOM; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MIANSERIN; PHOBIC DISORDERS; PILOT PROJECTS;

EID: 37249045504     PISSN: 08876185     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.janxdis.2007.01.005     Document Type: Article

References (43)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision (2000), American Psychiatric Association, Washington, DC
2. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Bobes J., Beidel D.C., et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry 59 17 (1998) 54-60
3. Beidel D.C. Social anxiety disorder: etiology and early clinical presentation. Journal of Clinical Psychiatry 59 17 (1998) 27-32
4. Beidel D.C., and Turner S.M. What are the adult consequences of childhood shyness?. Harvard Mental Health Letter 15 5 (1998) 8
5. Beidel D.C., Turner S.M., and Morris T.L. Psychopathology of childhood social phobia. Journal of the American Academy of Child and Adolescent Psychiatry 38 (1999) 643-650
6. Behnke K., Sogaard J., Martin S., Bauml J., Ravindran A.V., Agren H., et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. Journal of Clinical Psychopharmacology 23 4 (2003) 358-364
7. Benkert O., Szegedi A., and Kohnen R. Rapid onset of therapeutic action in major depression: a comparative trial of mirtazapine and paroxetine. American College of Neuropsychopharmacology, 37th Annual Meeting (1998), Las Croabas, Puerto Rico [abstract]
8. Biederman J., Rosenbaum J.F., Bolduc-Murphy E.A., Faraone S.V., Chaloff J., Hirshfeld D.R., et al. A 3-year follow-up of children with and without behavioral inhibition. Journal of the American Academy of Child and Adolescent Psychiatry 32 4 (1993) 814-821
9. Bremner J.D. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. Journal of Clinical Psychiatry 56 11 (1995) 519-525
10. Chavira D.A., and Stein M.B. Recent developments in child and adolescent social phobia. Current Psychiatry Report 2 4 (2000) 347-352
11. Compton S.N., Grant P.J., Chrisman A.K., Gammon P.J., Brown V.L., and March J.S. Sertraline in children and adolescents with social anxiety disorder: an open trial. Journal of the American Academy of Child and Adolescent Psychiatry 40 5 (2001) 564-571
12. Davidson J.R., Hughes D.L., George L.K., and Blazer D.G. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychological Medicine 23 3 (1993) 709-718
13. Fawcett J., and Barkin R.L. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. Journal of Affective Disorders 51 3 (1998) 267-285
14. Gambi F., De Berardis D., Campanella D., Carano A., Sepede G., Salini G., et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. Journal of Psychopharmacology 19 5 (2005) 483-487
15. Glover S., and Dixon P. Likelihood ratios: a simple and flexible statistic for empirical psychologists. Psychonomic Bulletin Review 11 (2004) 791-806
16. Goodnick P.J., Puig A., DeVane C.L., and Freund B.V. Mirtazapine in major depression with comorbid generalized anxiety disorder. Journal of Clinical Psychiatry 60 7 (1999) 446-448
17. Haapasalo-Pesu K.M., Vuola T., Lahelma L., and Marttunen M. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. Journal of Child and Adolescent Psychopharmacology 14 2 (2004) 175-184
18. Hansen C., Sanders S.L., Massaro S., and Last C.G. Predictors of severity of absenteeism in children with anxiety-based school refusal. Journal of Clinical Child Psychology 27 (1998) 246-254
19. Ialongo N., Edelsohn G., Werthamer-Larsson L., Crockett L., and Kellam S. The significance of self-reported anxious symptoms in first grade children: prediction to anxious symptoms and adaptive functioning in fifth grade. Journal of Child Psychology and Psychiatry 36 (1995) 427-437
20. Kovacs M. Children's Depression Inventory (CDI) (1992), Multi-Health Systems, Inc., New York, NY
21. Liebowitz M.R. Update on the diagnosis and treatment of social anxiety disorder. Journal of Clinical Psychiatry 60 18 (1999) 22-26
22. Mallinckrodt C.H., Carroll R.J., Debrota D.J., Dube S., Molenberghs G., Potter W.Z., et al. Assessing and interpreting treatment effects in longitudinal clinical trials with subject dropout. Biological Psychiatry 53 (2003) 754-760
23. Masia, C.L., Klein, R.G., & Liebowitz, M.R. (1999). The Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA) (available from Carrie Masia-Warner, NYU Child Study Center, 215 Lexington Avenue, 13th floor, New York, NY 10016).
24. Masia-Warner C.L., Storch E.A., Pincus D.B., Klein R.G., Heimberg R.G., and Liebowitz M.R. The Liebowitz Social Anxiety Scale for Children: an initial psychometric investigation. Journal of the American Academy of Child and Adolescent Psychiatry 42 (2003) 1076-1084
25. Muehlbacher M., Nickel M.K., Nickel C., Kettler C., Lahmann C., Gil F.P., et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 25 6 (2005) 580-583
26. National Institute of Mental Health (NIMH). CGI: clinical global impressions. In: Guy W., Bonato R.R., and Chase C. (Eds). Manual for the ECDEU assessment battery. 2nd revised ed. (1970), National Institute of Mental Health, Bethesda, MD
27. Organon. (2001). NDA 20-415 SE5-011 Drug: Mitrazapine (Remeron). Pediatric Supplement SE5-011. Retrieved May 7, 2001, from http://www.fda.gov/cder/foi/esum/2004/20415SE5_011_Mirtazapine 20MO 20ReviewFIN.pdf.
28. Pallanti S., Quercioli L., and Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. Journal of Clinical Psychiatry 65 10 (2004) 1394-1399
29. Pine D.S., Cohen P., Gurley D., Brook J., and Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Archives of General Psychiatry 55 (1998) 56-64
30. Reich W., Welner Z., and Herjanic B. Diagnostic Interview for Children and Adolescents-IV (DICA-IV) (1997), Multi-Health Systems, Toronto, Canada
31. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine 344 17 (2001) 1279-1285
32. In: Reynolds C., and Richmond B. (Eds). Revised Children's Manifest Anxiety Scale manual (1985), Western Psychological Services, Los Angeles, CA
33. Schneier F.R., Johnson J., Hornig C.D., Liebowitz M.R., and Weissman M.M. Social phobia: comorbidity and morbidity in an epidemiologic sample. Archives of General Psychiatry 49 (1992) 282-288
34. Schneier F.R., Heckelman L.R., Campeas R., Fallon B.A., Gitow A., Street L., et al. Functional impairment in social phobia. Journal of Clinical Psychiatry 55 (1994) 322-331
35. Schutte, A.-J., Vester, E., & Kremer, C. (1999). Tolerability of mirtazapine versus SSRIs [abstract]. WPA, Hamburg.
36. Stein M.B. Medication treatments for panic disorder and social phobia. Depression and Anxiety 7 3 (1998) 134-138
37. Stein M.B., Fuetsch M., Muller N., Hofler M., Lieb R., and Wittchen H.U. Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults. Archives of General Psychiatry 58 3 (2001) 251-256
38. Turner S.M., Beidel D.C., and Townsley R.M. Social phobia: a comparison of specific and generalized subtypes and avoidant personality disorder. Journal of Abnormal Psychology 101 2 (1992) 340-343
39. Van Veen J.F., Van Vliet I.M., and Westenberg H.G. Mirtazapine in social anxiety disorder: a pilot study. International Clinical Psychopharmacology 17 6 (2002) 315-317
40. Wagner K.D., Berard R., Stein M.B., Wetherhold E., Carpenter D.J., Perera P., et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Archives of General Psychiatry 61 11 (2004) 1153-1162
41. Wheatley D.P., van Moffaert M., Timmerman L., and Kremer C.M. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. Journal of Clinical Psychiatry 59 6 (1998) 306-312
42. Wittchen H.U., Stein M.B., and Kessler R.C. Social fears and social phobia in a community sample of adolescents and young adults: prevalence, risk factors and co-morbidity. Psychological Medicine 29 2 (1999) 309-323
43. Woodward L.J., and Fergusson D.M. Life course outcomes of young people with anxiety disorders in adolescence. Journal of the American Academy of Child and Adolescent Psychiatry 40 9 (2001) 1086-1093